Loading…
Thymic carcinoma. A distinct clinical entity responsive to chemotherapy
Background. Thymic carcinomas are rare tumors of the anterior mediastinum. These tumors are distinct thymic neoplasms that differ from their more common counterpart, thymoma. As opposed to thymomas, thymic carcinomas are histologically malignant neoplasms with a clinical course that tends to be much...
Saved in:
| Published in: | Cancer 1993-02, Vol.71 (4), p.1219-1223 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4518-896675ed769836ecef11c359b604c41b97ecb7072d9163a4260a3339824b81553 |
| container_end_page | 1223 |
| container_issue | 4 |
| container_start_page | 1219 |
| container_title | Cancer |
| container_volume | 71 |
| creator | Weide, Lamont G. Ulbright, Thomas M. Loehrer, Patrick J. Williams, Stephen D. |
| description | Background. Thymic carcinomas are rare tumors of the anterior mediastinum. These tumors are distinct thymic neoplasms that differ from their more common counterpart, thymoma. As opposed to thymomas, thymic carcinomas are histologically malignant neoplasms with a clinical course that tends to be much more aggressive than that of patients with thymoma.
Methods. Between 1984 and 1990, five patients with thymic carcinoma treated with cisplatin‐based combination chemotherapy were seen at Indiana University Hospital. These patients' diagnoses, courses, and treatments were reviewed.
Results. Three patients responded (two completely) to cisplatin‐based chemotherapy.
Conclusions. This form of chemotherapy merits additional study in such patients, and our experience indicates that at least some will have clinically meaningful responses. The optimum regimen is unclear, but would contain cisplatin and probably should be similar to that used in germ cell tumors. |
| doi_str_mv | 10.1002/1097-0142(19930215)71:4<1219::AID-CNCR2820710408>3.0.CO;2-B |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75578082</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75578082</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4518-896675ed769836ecef11c359b604c41b97ecb7072d9163a4260a3339824b81553</originalsourceid><addsrcrecordid>eNqVkFuLE0EQhRtR1rj6E4R5En2YWNWX6e4oQnbUdWExICsIPhQ9nQ5pmUucnrjMv98JiQv6IPhUFOfUqcPHWIkwRwD-GsHqHFDyl2itAI7qlcaFfIsc7WKxvHqfl5_LL9xw0AgSzDsxh3m5esPziwdsdn_9kM0AwORKim-P2ZOUfkyr5kqcsTMjhdK2mLHLm-3YRJ951_vYdo2bZ8tsHdMQWz9kvo5t9K7OQjvEYcz6kHZdm-KvkA1d5reh6YZt6N1ufMoebVydwrPTPGdfP364KT_l16vLq3J5nXup0OTGFoVWYa0La0QRfNggeqFsVYD0Eiurg6_01HJtsRBO8gKcEMIaLiuDSolz9uKYu-u7n_uQBmpi8qGuXRu6fSKtlDZg-GT8fjT6vkupDxva9bFx_UgIdMBMB1B0AEW_MZNGknTATDRhpj8xkyCgckWcLqb056ca-6oJ6_vsE9dJ3xz121iH8f9e__PzX4q4A52LmQE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75578082</pqid></control><display><type>article</type><title>Thymic carcinoma. A distinct clinical entity responsive to chemotherapy</title><source>EZB Electronic Journals Library</source><creator>Weide, Lamont G. ; Ulbright, Thomas M. ; Loehrer, Patrick J. ; Williams, Stephen D.</creator><creatorcontrib>Weide, Lamont G. ; Ulbright, Thomas M. ; Loehrer, Patrick J. ; Williams, Stephen D.</creatorcontrib><description>Background. Thymic carcinomas are rare tumors of the anterior mediastinum. These tumors are distinct thymic neoplasms that differ from their more common counterpart, thymoma. As opposed to thymomas, thymic carcinomas are histologically malignant neoplasms with a clinical course that tends to be much more aggressive than that of patients with thymoma.
Methods. Between 1984 and 1990, five patients with thymic carcinoma treated with cisplatin‐based combination chemotherapy were seen at Indiana University Hospital. These patients' diagnoses, courses, and treatments were reviewed.
Results. Three patients responded (two completely) to cisplatin‐based chemotherapy.
Conclusions. This form of chemotherapy merits additional study in such patients, and our experience indicates that at least some will have clinically meaningful responses. The optimum regimen is unclear, but would contain cisplatin and probably should be similar to that used in germ cell tumors.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19930215)71:4<1219::AID-CNCR2820710408>3.0.CO;2-B</identifier><identifier>PMID: 8435796</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Anaplasia ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cell Nucleolus - ultrastructure ; Cell Nucleus - ultrastructure ; chemotherapy ; cisplatin ; Cisplatin - administration & dosage ; Cytoplasm - ultrastructure ; Desmosomes - ultrastructure ; Epithelium - pathology ; Female ; Humans ; Intercellular Junctions - ultrastructure ; Intermediate Filaments - ultrastructure ; Male ; Mediastinal Neoplasms - drug therapy ; Mediastinal Neoplasms - pathology ; mediastinum ; Middle Aged ; Thymoma - drug therapy ; Thymoma - pathology ; thymus ; Thymus Neoplasms - drug therapy ; Thymus Neoplasms - pathology</subject><ispartof>Cancer, 1993-02, Vol.71 (4), p.1219-1223</ispartof><rights>Copyright © 1993 American Cancer Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4518-896675ed769836ecef11c359b604c41b97ecb7072d9163a4260a3339824b81553</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8435796$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weide, Lamont G.</creatorcontrib><creatorcontrib>Ulbright, Thomas M.</creatorcontrib><creatorcontrib>Loehrer, Patrick J.</creatorcontrib><creatorcontrib>Williams, Stephen D.</creatorcontrib><title>Thymic carcinoma. A distinct clinical entity responsive to chemotherapy</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background. Thymic carcinomas are rare tumors of the anterior mediastinum. These tumors are distinct thymic neoplasms that differ from their more common counterpart, thymoma. As opposed to thymomas, thymic carcinomas are histologically malignant neoplasms with a clinical course that tends to be much more aggressive than that of patients with thymoma.
Methods. Between 1984 and 1990, five patients with thymic carcinoma treated with cisplatin‐based combination chemotherapy were seen at Indiana University Hospital. These patients' diagnoses, courses, and treatments were reviewed.
Results. Three patients responded (two completely) to cisplatin‐based chemotherapy.
Conclusions. This form of chemotherapy merits additional study in such patients, and our experience indicates that at least some will have clinically meaningful responses. The optimum regimen is unclear, but would contain cisplatin and probably should be similar to that used in germ cell tumors.</description><subject>Adult</subject><subject>Anaplasia</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cell Nucleolus - ultrastructure</subject><subject>Cell Nucleus - ultrastructure</subject><subject>chemotherapy</subject><subject>cisplatin</subject><subject>Cisplatin - administration & dosage</subject><subject>Cytoplasm - ultrastructure</subject><subject>Desmosomes - ultrastructure</subject><subject>Epithelium - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Intercellular Junctions - ultrastructure</subject><subject>Intermediate Filaments - ultrastructure</subject><subject>Male</subject><subject>Mediastinal Neoplasms - drug therapy</subject><subject>Mediastinal Neoplasms - pathology</subject><subject>mediastinum</subject><subject>Middle Aged</subject><subject>Thymoma - drug therapy</subject><subject>Thymoma - pathology</subject><subject>thymus</subject><subject>Thymus Neoplasms - drug therapy</subject><subject>Thymus Neoplasms - pathology</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><recordid>eNqVkFuLE0EQhRtR1rj6E4R5En2YWNWX6e4oQnbUdWExICsIPhQ9nQ5pmUucnrjMv98JiQv6IPhUFOfUqcPHWIkwRwD-GsHqHFDyl2itAI7qlcaFfIsc7WKxvHqfl5_LL9xw0AgSzDsxh3m5esPziwdsdn_9kM0AwORKim-P2ZOUfkyr5kqcsTMjhdK2mLHLm-3YRJ951_vYdo2bZ8tsHdMQWz9kvo5t9K7OQjvEYcz6kHZdm-KvkA1d5reh6YZt6N1ufMoebVydwrPTPGdfP364KT_l16vLq3J5nXup0OTGFoVWYa0La0QRfNggeqFsVYD0Eiurg6_01HJtsRBO8gKcEMIaLiuDSolz9uKYu-u7n_uQBmpi8qGuXRu6fSKtlDZg-GT8fjT6vkupDxva9bFx_UgIdMBMB1B0AEW_MZNGknTATDRhpj8xkyCgckWcLqb056ca-6oJ6_vsE9dJ3xz121iH8f9e__PzX4q4A52LmQE</recordid><startdate>19930215</startdate><enddate>19930215</enddate><creator>Weide, Lamont G.</creator><creator>Ulbright, Thomas M.</creator><creator>Loehrer, Patrick J.</creator><creator>Williams, Stephen D.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930215</creationdate><title>Thymic carcinoma. A distinct clinical entity responsive to chemotherapy</title><author>Weide, Lamont G. ; Ulbright, Thomas M. ; Loehrer, Patrick J. ; Williams, Stephen D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4518-896675ed769836ecef11c359b604c41b97ecb7072d9163a4260a3339824b81553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>Anaplasia</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cell Nucleolus - ultrastructure</topic><topic>Cell Nucleus - ultrastructure</topic><topic>chemotherapy</topic><topic>cisplatin</topic><topic>Cisplatin - administration & dosage</topic><topic>Cytoplasm - ultrastructure</topic><topic>Desmosomes - ultrastructure</topic><topic>Epithelium - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Intercellular Junctions - ultrastructure</topic><topic>Intermediate Filaments - ultrastructure</topic><topic>Male</topic><topic>Mediastinal Neoplasms - drug therapy</topic><topic>Mediastinal Neoplasms - pathology</topic><topic>mediastinum</topic><topic>Middle Aged</topic><topic>Thymoma - drug therapy</topic><topic>Thymoma - pathology</topic><topic>thymus</topic><topic>Thymus Neoplasms - drug therapy</topic><topic>Thymus Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weide, Lamont G.</creatorcontrib><creatorcontrib>Ulbright, Thomas M.</creatorcontrib><creatorcontrib>Loehrer, Patrick J.</creatorcontrib><creatorcontrib>Williams, Stephen D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weide, Lamont G.</au><au>Ulbright, Thomas M.</au><au>Loehrer, Patrick J.</au><au>Williams, Stephen D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thymic carcinoma. A distinct clinical entity responsive to chemotherapy</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1993-02-15</date><risdate>1993</risdate><volume>71</volume><issue>4</issue><spage>1219</spage><epage>1223</epage><pages>1219-1223</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Background. Thymic carcinomas are rare tumors of the anterior mediastinum. These tumors are distinct thymic neoplasms that differ from their more common counterpart, thymoma. As opposed to thymomas, thymic carcinomas are histologically malignant neoplasms with a clinical course that tends to be much more aggressive than that of patients with thymoma.
Methods. Between 1984 and 1990, five patients with thymic carcinoma treated with cisplatin‐based combination chemotherapy were seen at Indiana University Hospital. These patients' diagnoses, courses, and treatments were reviewed.
Results. Three patients responded (two completely) to cisplatin‐based chemotherapy.
Conclusions. This form of chemotherapy merits additional study in such patients, and our experience indicates that at least some will have clinically meaningful responses. The optimum regimen is unclear, but would contain cisplatin and probably should be similar to that used in germ cell tumors.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8435796</pmid><doi>10.1002/1097-0142(19930215)71:4<1219::AID-CNCR2820710408>3.0.CO;2-B</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1993-02, Vol.71 (4), p.1219-1223 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75578082 |
| source | EZB Electronic Journals Library |
| subjects | Adult Anaplasia Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cell Nucleolus - ultrastructure Cell Nucleus - ultrastructure chemotherapy cisplatin Cisplatin - administration & dosage Cytoplasm - ultrastructure Desmosomes - ultrastructure Epithelium - pathology Female Humans Intercellular Junctions - ultrastructure Intermediate Filaments - ultrastructure Male Mediastinal Neoplasms - drug therapy Mediastinal Neoplasms - pathology mediastinum Middle Aged Thymoma - drug therapy Thymoma - pathology thymus Thymus Neoplasms - drug therapy Thymus Neoplasms - pathology |
| title | Thymic carcinoma. A distinct clinical entity responsive to chemotherapy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A37%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thymic%20carcinoma.%20A%20distinct%20clinical%20entity%20responsive%20to%20chemotherapy&rft.jtitle=Cancer&rft.au=Weide,%20Lamont%20G.&rft.date=1993-02-15&rft.volume=71&rft.issue=4&rft.spage=1219&rft.epage=1223&rft.pages=1219-1223&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/1097-0142(19930215)71:4%3C1219::AID-CNCR2820710408%3E3.0.CO;2-B&rft_dat=%3Cproquest_cross%3E75578082%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4518-896675ed769836ecef11c359b604c41b97ecb7072d9163a4260a3339824b81553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=75578082&rft_id=info:pmid/8435796&rfr_iscdi=true |